Streetbeat News

CELZ

Creative Medical Technology Holdings, Inc.

https://www.creativemedicaltechnology.com

Industry

Biotechnology

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Open

3.18

Mkt cap

7.5M

Volume

115K

High

3.26

P/E Ratio

-0.84

52-wk high

6.90

Low

2.89

Div yield

N/A

52-wk low

1.96

Creative Medical Technology Holdings has received FDA clearance to expand dose escalation in its clinical trial for CELZ-201-DDT, a treatment for chronic lower back pain. Positive interim data supports moving towards a potential Phase 3 study.

Portfolio Pulse from

March 20, 2025 | 12:00 pm

Portfolio Pulse from

March 20, 2025 | 12:00 pm

Creative Medical Technology Holdings (Nasdaq: CELZ) has announced agreements for the exercise of warrants, expected to generate $3.7 million in gross proceeds. The exercise involves 837,104 shares at $4.42 per share.

Portfolio Pulse from

March 06, 2025 | 1:30 pm

Creative Medical Technology Holdings reported positive mid-term follow-up data from its StemSpine® pilot study, showing significant reduction in opioid use and improvements in pain and mobility for chronic lower back pain patients using AlloStem™ cells.

Portfolio Pulse from

February 14, 2025 | 12:15 pm

Creative Medical Technology Holdings, Inc. reported positive one-year results for its AlloStem™ Type 2 Diabetes program, showing significant efficacy and no serious adverse effects with CELZ-201.

Portfolio Pulse from

February 11, 2025 | 2:45 pm

Creative Medical Technology Holdings (NASDAQ: CELZ) has expanded its collaboration with Greenstone Biosciences to enhance its iPSCelz pipeline using AI for diabetes treatment.

Portfolio Pulse from

February 05, 2025 | 1:45 pm

Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive initial safety, tolerability, and efficacy data from the first cohort of its Phase 1/2 trial for CELZ-201-DDT, a stem cell-based treatment for chronic back pain due to degenerative disc disease.

Portfolio Pulse from

January 30, 2025 | 2:45 pm

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced a positive independent safety review for its ADAPT clinical trial, validating the safety and potential of CELZ-201 for treating chronic lower back pain.

Portfolio Pulse from

November 13, 2024 | 2:15 pm

Creative Medical Technology shares declined following the announcement of a $1.85 million registered direct offering priced at the market under Nasdaq rules.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:25 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals were among the top gainers, while Alto Neuroscience and Ensysce Biosciences saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.